Cargando…

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019

BACKGROUND: Multiple myeloma (MM) is a major health concern. Understanding the different burden and tendency of MM in different regions is crucial for formulating specific local strategies. Therefore, we evaluated the epidemiologic patterns and explored the risk factors for MM death. METHODS: Data o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Linghui, Yu, Qin, Wei, Guoqing, Wang, Linqin, Huang, Yue, Hu, Kejia, Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152089/
https://www.ncbi.nlm.nih.gov/pubmed/34034700
http://dx.doi.org/10.1186/s12885-021-08280-y
_version_ 1783698535378583552
author Zhou, Linghui
Yu, Qin
Wei, Guoqing
Wang, Linqin
Huang, Yue
Hu, Kejia
Hu, Yongxian
Huang, He
author_facet Zhou, Linghui
Yu, Qin
Wei, Guoqing
Wang, Linqin
Huang, Yue
Hu, Kejia
Hu, Yongxian
Huang, He
author_sort Zhou, Linghui
collection PubMed
description BACKGROUND: Multiple myeloma (MM) is a major health concern. Understanding the different burden and tendency of MM in different regions is crucial for formulating specific local strategies. Therefore, we evaluated the epidemiologic patterns and explored the risk factors for MM death. METHODS: Data on MM were collected from the 2019 Global Burden of Disease study. We used incidence, mortality, and disability adjusted life-years to estimate the global, regional, and national burden of MM. RESULTS: In 2019, there were 155,688 (95% UI, 136,585 – 172,577) MM cases worldwide, of which 84,516 (54.3%, 70,924 – 94,910) were of men. The age-standardized incidence rate (ASIR) was 1.72/100,000 persons (95% UI, 1.59–1.93) in 1990 and 1.92/100,000 persons (95% UI, 1.68–2.12) in 2019. The number of MM deaths increased 1.19-fold from 51,862 (95% UI, 47,710–58,979) in 1990 to 113,474 (95% UI, 99,527 – 121,735) in 2019; the age-standardized death rate (ASDR) was 1.42/100,000 persons (95% UI, 1.24–1.52) in 2019. In recent 15 years, ASDR showed a steady tendency for men, and a downward tendency for women. Countries with high social-demographic indexes exhibited a higher ASIR and ASDR. Australasia, North America, and Western Europe had the highest ASIR and ASDR, with 46.3% incident cases and 41.8% death cases. Monaco had the highest ASIR and ASDR, which was almost half as high as the second highest country Barbados. In addition, United Arab Emirates and Qatar had the largest growth multiple in ASIR and ASDR, which was twice the third country Djibouti. CONCLUSIONS: Globally, incident and death MM cases have more than doubled over the past 30 years. The increasing global burden may continue with population aging, whereas mortality may continue to decrease with the progression of medical technology. The global burden pattern of MM was diverse, therefore specific local strategies based on different burden patterns for MM are necessary. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08280-y.
format Online
Article
Text
id pubmed-8152089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81520892021-05-26 Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019 Zhou, Linghui Yu, Qin Wei, Guoqing Wang, Linqin Huang, Yue Hu, Kejia Hu, Yongxian Huang, He BMC Cancer Research BACKGROUND: Multiple myeloma (MM) is a major health concern. Understanding the different burden and tendency of MM in different regions is crucial for formulating specific local strategies. Therefore, we evaluated the epidemiologic patterns and explored the risk factors for MM death. METHODS: Data on MM were collected from the 2019 Global Burden of Disease study. We used incidence, mortality, and disability adjusted life-years to estimate the global, regional, and national burden of MM. RESULTS: In 2019, there were 155,688 (95% UI, 136,585 – 172,577) MM cases worldwide, of which 84,516 (54.3%, 70,924 – 94,910) were of men. The age-standardized incidence rate (ASIR) was 1.72/100,000 persons (95% UI, 1.59–1.93) in 1990 and 1.92/100,000 persons (95% UI, 1.68–2.12) in 2019. The number of MM deaths increased 1.19-fold from 51,862 (95% UI, 47,710–58,979) in 1990 to 113,474 (95% UI, 99,527 – 121,735) in 2019; the age-standardized death rate (ASDR) was 1.42/100,000 persons (95% UI, 1.24–1.52) in 2019. In recent 15 years, ASDR showed a steady tendency for men, and a downward tendency for women. Countries with high social-demographic indexes exhibited a higher ASIR and ASDR. Australasia, North America, and Western Europe had the highest ASIR and ASDR, with 46.3% incident cases and 41.8% death cases. Monaco had the highest ASIR and ASDR, which was almost half as high as the second highest country Barbados. In addition, United Arab Emirates and Qatar had the largest growth multiple in ASIR and ASDR, which was twice the third country Djibouti. CONCLUSIONS: Globally, incident and death MM cases have more than doubled over the past 30 years. The increasing global burden may continue with population aging, whereas mortality may continue to decrease with the progression of medical technology. The global burden pattern of MM was diverse, therefore specific local strategies based on different burden patterns for MM are necessary. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08280-y. BioMed Central 2021-05-25 /pmc/articles/PMC8152089/ /pubmed/34034700 http://dx.doi.org/10.1186/s12885-021-08280-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Linghui
Yu, Qin
Wei, Guoqing
Wang, Linqin
Huang, Yue
Hu, Kejia
Hu, Yongxian
Huang, He
Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title_full Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title_fullStr Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title_full_unstemmed Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title_short Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
title_sort measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152089/
https://www.ncbi.nlm.nih.gov/pubmed/34034700
http://dx.doi.org/10.1186/s12885-021-08280-y
work_keys_str_mv AT zhoulinghui measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT yuqin measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT weiguoqing measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT wanglinqin measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT huangyue measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT hukejia measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT huyongxian measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019
AT huanghe measuringtheglobalregionalandnationalburdenofmultiplemyelomafrom1990to2019